{
  "doc_id": "PIIS0923753422047810",
  "created_date": "2022",
  "country:": "unknown",
  "chunks": [
    {
      "heading": "SPECIAL ARTICLE",
      "text": "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical 5 Practice Guideline for diagnosis, treatment and follow-up\n1 2 3 4 5,6 7 8 9 10,11 L. E. Hendriks , K. M. Kerr , J. Menis , T. S. Mok , U. Nestle , A. Passaro , S. Peters , D. Planchard , E. F. Smit , (cid:1) 12 13,14 15 B. J. Solomon , G. Veronesi & M. Reck , on behalf of the ESMO Guidelines Committee\nFigure 2. Treatment algorithm for stage IV mNSCLC with EGFR -activating mutation. fi Purple: generalcategories orstrati cation;blue: systemicanticancer therapy;turquoise:combination oftreatmentsorothersystemictreatments;white: otheraspects of management. cfDNA, cell-free DNA; ChT, chemotherapy; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of fi Molecular Targets; FDA, Food and Drug Administration; MCBS, ESMO-Magnitude of Clinical Bene t Scale; mNSCLC, metastatic non-small-cell lung cancer; NGS, next- generation sequencing; PS, performance status; RT, radiotherapy; TKI, tyrosine kinase inhibitor. a 111 ESMO-MCBS v1.1 was used to calculate scores for new therapies/indications approved by the EMA or FDA.The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee  b Preferred option. c fi ESCATscoresapplytoalterationsfromgenomic-drivenanalysesonly.Thesescoreshavebeende nedbytheguidelineauthorsandvalidatedbytheESMOTranslational 4 Research and Precision Medicine Working Group. See Supplementary Table S1, available at  for more information on ESCATscores. d EGFR Recommended treatment option for patients with a major uncommon, non-exon 20insertion, sensitising mutation[III, B;ESMO-MCBSv1.1score:4 forafatinib; ESCAT: I-B]. e fi ESMO-MCBS v1.1 score for the combination of bevacizumab with ge tinib or erlotinib. f Not EMA approved. g fi Patients who have moderate radiological progression with ongoing clinical bene t may continue with EGFR TKIs [III, A].\nfi fi e is still acceptable to sequentially use rst- or second- Furthermore, with longer follow-up the OS bene t for ChT fi fi fi generation EGFR TKIs (e.g. erlotinib, ge tinib, afatinib and ge tinib was not statistically signi cant anymore in the fi 26 dacomitinib) followed by osimertinib, speci cally for T790M- NEJ009 trial. Moreover, toxicity, inconvenience for patients positive resistant disease (occurring in approximately half of and costs increase with adding another treatment.Therefore, fi the patients). Other rst-line strategy options are combina- single-agent(third-generation)EGFRTKIsarestillonestandard fi tions of EGFR TKIs and ChT [not European Medicines Agency rst-line treatment. (EMA) approved] or combination of EGFR TKIs and anti- fi angiogenics, which have shown signi cant improvement in First-line EGFR TKIs for uncommon EGFR mutations. e PFS in phase III RCTs (e.g. erlotinib bevacizumab and erloti- Although the majority of activating EGFR mutations are e 21-25 nib ramucirumab). Foranti-angiogenics,however,either exon 19 deletions or the exon 21 L858R point mutation, fi 21-23 noOSbene twasobservedorOSdataarenotyetmature. 10%-20% of patients present with an uncommon, non-exon e fi fi fi For ChT ge tinib combinations, only superiority over rst- 20 insertion mutation. In retrospective studies, rst- 24,25 generation EGFR TKIs has been demonstrated for OS, generation EGFR TKIs result in a lower overall response fi whereas the bene t compared with osimertinib is not clear. rate (ORR) and PFS compared with exon 19 deletions or\nFigure 3. Treatment algorithm for stage IV mNSCLC with ALK translocation. fi Purple: generalcategories orstrati cation;blue: systemicanticancer therapy;turquoise:combination oftreatmentsorothersystemictreatments;white: otheraspects of management. ALK, anaplastic lymphoma kinase; ChT, chemotherapy; EMA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of Molecular Targets; FDA, Food fi and Drug Administration; MCBS, ESMO-Magnitude of Clinical Bene t Scale; mNSCLC, metastatic non-small-cell lung cancer; RT, radiotherapy; TKI, tyrosine kinase inhibitor. a 111 ESMO-MCBS v1.1 was used to calculate scores for new therapies/indications approved by the EMA or FDA.The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee  b Preferred option. c fi ESCATscoresapplytoalterationsfromgenomic-drivenanalysesonly.Thesescoreshavebeende nedbytheguidelineauthorsandvalidatedbytheESMOTranslational 4 Research and Precision Medicine Working Group. See Supplementary Table S1, available at  for more information on ESCATscores.\nincidence with brigatinib included increased creatine kinase mPFS than crizotinib [not reached (NR) versus 9.3 months; 46 levels, cough and hypertension. Interstitial lung disease HR 0.28, 95% CI 0.19-0.41]. Intracranial ORR and time to (ILD)/pneumonitis occurred in 4% of patients. intracranial progression were superior for lorlatinib. The most common AEs of any grade with lorlatinib were Ensartinib (not EMA approved). The eXalt3 phase III RCT hyperlipidaemia, oedema, increased weight, peripheral ¼ ( N 290) comparing ensartinib with crizotinib demon- neuropathy and cognitive effects. Lorlatinib was associated strated improved mPFS with ensartinib (25.8 versus 12.7 with more grade 3-4 AEs (mainly altered lipid levels) than 45 months; HR 0.51, 95% CI 0.35-0.72). Rash, elevated crizotinib (72% versus 56%). transaminases and pruritis were the most common AEs. Of note, there have not been direct comparisons be- tween the newer-generation ALK TKIs. The choice of drug ¼ Lorlatinib. In the CROWN phase III RCT ( N 296) lorlatinib fl will be in uenced by factors including the extent of CNS fi resulted in a signi cantly longer independently-determined\nFigure 5. Treatment algorithm for stage IV mNSCLC with BRAF V600 mutation . fi Purple: generalcategories orstrati cation;blue: systemicanticancer therapy;turquoise:combination oftreatmentsorothersystemictreatments;white: otheraspects of management. ChT, chemotherapy, EMA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of Molecular Targets; FDA, Food and Drug Administration; MCBS, fi ESMO-Magnitude of Clinical Bene t Scale; mNSCLC, metastatic non-small-cell lung cancer; RT, radiotherapy. a 111 ESMO-MCBS v1.1 was used to calculate scores for new therapies/indications approved by the EMA or FDA.The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee  b fi ESCATscoresapplytoalterationsfromgenomic-drivenanalysesonly.Thesescoreshavebeende nedbytheguidelineauthorsandvalidatedbytheESMOTranslational 4 Research and Precision Medicine Working Group. See Supplementary Table S1, available at  for more information on ESCATscores.\nfi pretreated and treatment-naive patients, respectively, the investigating the ef cacy of single-agent ICI in oncogene- fi mOS was 18.2 months (95% CI 14.3-28.6 months; 4- and addicted mNSCLC, con rmed that patients with BRAF V600- ¼ 71 5-year survival rates: 34% and 22%, respectively) and 17.3 mutated ( n 28 patients) showed a response rate of 26%. months (95% CI 12.3-40.2 months; 4- and 5-year survival RET fusions 70 rates: 26% and 19%, respectively). These results represent fi a clinically signi cant improvement over both single-agent Selpercatinib, a rearranged during transfection (RET)- dabrafenib and conventional ChT. Dabrafenib in combina- selective inhibitor, was evaluated in the LIBRETTO-001 72 tion with trametinib is recommended for the treatment of phase I-II study in patients with RET -rearranged NSCLC. patients with BRAF V600 - mutated advanced or metastatic The ORR was 64% (95% CI 54% to 73%) in 105 platinum- NSCLC (trial only enrolled V600E-positive patients). Very few pretreated patients and 85% (95% CI 70% to 94%) in 39 fi data on the bene t of single-agent ICI in the BRAF -mutated treatment-naive patients. The mDoR was 17.5 months in population are available. Results of the international pretreated and NR for treatment-naive patients. Pralsetinib, IMMUNOTARGET study (43 patients with BRAF -mutated, another RET-selective inhibitor, was evaluated in the AR- 73 40% V600E) showed poor outcomes in BRAF -mutated pa- ROW study; the ORR was 59% (95% CI 50% to 67%) in 136 37 tients, with an ORR of 24% and a mPFS of 3.1 months. platinum-pretreated patients and 72% (95% CI 60% to 82%) Consistent with this, another retrospective study in 75 treatment-naive patients. The mDoR was NR in\n(cid:3) e e Role of minimally-invasive procedures in stage IV The combination of atezolizumab bevacizumab e paclitaxel carboplatin may be considered as a treatment Details on the role of minimally-invasive procedures and option for patients with EGFR TKI failure, PS 0-1 and recommendations are covered in the ESMO CPG on non- no contraindication for ICIs [III, B; ESMO-MCBS v1.1 10 oncogene-addicted mNSCLC. score: 3]. (cid:3) Single-agent ICIs may be considered as a treatment op- tion only after progression on EGFR TKIs and ChT [IV, C]. Recommendations ALK -rearranged NSCLC EGFR -mutated NSCLC (cid:3) fi (cid:3) Patients should be treated in the rst-line setting with Allpatientswithasensitising EGFR mutationshouldreceive fi alectinib, brigatinib or lorlatinib [I, A; ESMO-MCBS v1.1 rst-line EGFR TKIs irrespective of clinical parameters score: 4; ESCAT: I-A]. These options are preferred over including PS, gender,tobacco exposure and histology [I, A]. (cid:3) fi crizotinib or ceritinib [I, B; ESMO-MCBS v1.1 score: 4; Osimertinib is the preferable rst-line treatment option ESCAT: I-A]. for patients with a classical activating EGFR mutation (cid:3) Alectinib is recommended in patients who progress on (exon 19 deletion or exon 21 L858R), especially for pa- treatment with, or are intolerant to, crizotinib [I, A; tients with CNS metastases [I, A; ESMO-Magnitude of fi ESMO-MCBS v1.1 score: 4; ESCAT: I-A]. Clinical Bene t (ESMO-MCBS) v1.1 score: 4; ESCAT: I-A]. (cid:3) (cid:3) fi Brigatinib and ceritinib represent additional treatment Erlotinib, ge tinib, afatinib and dacomitinib are other fi options at crizotinib resistance [brigatinib: III, A; ESMO- rst-line single-agent treatment options [erlotinib and fi MCBS v1.1 score: 4; ESCAT: I-A; ceritinib: I, A; ESMO- ge tinib: I, B; ESMO-MCBS v1.1 score: 4; ESCAT: I-A; afa- MCBS v1.1 score: 4; ESCAT: I-A]. tinib: I, B; ESMO-MCBS v1.1 score: 5; ESCAT: I-A; dacomi- (cid:3) In patients who progress after a second-generation ALK tinib: I, B; ESMO-MCBS v1.1 score: 3; ESCAT: I-A]. (cid:3) fi fi TKI, the newer-generation ALK inhibitor lorlatinib is an Another rst-line option is ge tinib combined with e option [III, A; ESMO-MCBS v1.1 score: 4; ESCAT: I-A]. carboplatin pemetrexed [I, B; not EMA approved]. (cid:3) Following progression on lorlatinib, ChT with a (cid:3) EGFR TKIs combined with anti-angiogenic therapy are e platinum pemetrexed-based combination is recommen- fi additional rst-line treatment options, including ded [III, A]. e erlotinib bevacizumab [I, B; ESMO-MCBS v1.1 score: 2; (cid:3) e Following progression on lorlatinib, atezolizumab beva- ESCAT: I-A; EMA approved, not FDA approved] or e e e cizumab paclitaxel carboplatin can be considered erlotinib ramucirumab [I, B; ESMO-MCBS v1.1 score: [III, B; ESMO-MCBS v1.1 score: 3]. 3; ESCAT: I-A]. (cid:3) Considering toxicity, cost increases with adding addi- Treatment of ROS1 -rearranged NSCLC tional treatments and patient inconvenience, single- (cid:3) fi Crizotinib or entrectinib is recommended in the rst-line fi agent EGFR TKIs are still a standard rst-line treatment setting [III, A; ESMO-MCBS v1.1 score: 3; ESCAT: I-B]. [I, A; ESCAT: I-A]. (cid:3) Entrectinib, if available, is preferred over crizotinib in pa- (cid:3) Afatinib or osimertinib is a recommended treatment op- tients with brain metastases [III, A; ESMO-MCBS v1.1 tion for patients with a major uncommon, non-exon 20 score: 3; ESCAT: I-B]. insertion, sensitising EGFR mutation [III, B; ESMO-MCBS (cid:3) fi Repotrectinib, if available, is an option in the rst-line v1.1 score: 4 for afatinib; ESCAT: I-B]. setting but is not EMA approved [III, B; ESCAT: I-B]. (cid:3) Patients who have moderate radiological progression (cid:3) fi If patients have received crizotinib in the rst-line fi with ongoing clinical bene t may continue with EGFR setting, they may be offered a newer-generation TKI if TKIs [III, A]. available [III, A] (no EMA approval) or platinum-based (cid:3) fi fi Upon resistance to rst-line rst- or second-generation ChT in the second-line setting [IV, A]. EGFR TKIs, patients should be tested for the presence BRAF mutations of the EGFR exon 20 T790M mutation from plasma (cid:3) e e BRAF MEK inhibition using dabrafenib trametinib is rec- cfDNA and/or tumour re-biopsy [I, A]. ommended [III, A; ESMO-MCBS v1.1 score: 2; ESCAT: I-B]. (cid:3) Patients with T790M-positive resistance should receive (cid:3) e If patients have received BRAF MEK inhibition in the osimertinib as second-line therapy [I, A; ESMO-MCBS fi rst-line setting, they may be offered platinum-based v 1.1 score: 4; ESCAT: I-A], whereas T790M-negative resis- ChT with or without immunotherapy in the second-line tance should be treated with platinum-based ChT [III, A]. setting, if they do not have a smoking history [IV, A]. (cid:3) Genomic analysis by NGS (tissue, or cfDNA followed by For patients with a smoking history, immunotherapy tissue if no target is found with cfDNA) should be with or without ChT should be considered as per made available to a patient who develops resistance to the ESMO CPG on non-oncogene-addicted mNSCLC osimertinib [III, C]. 10 [IV, B]. (cid:3) Platinum-doublet ChT is the SoC upon progression on RET fusions osimertinib [III, A]. Clinical trial enrolment is encouraged, (cid:3) Treatment with selpercatinib or pralsetinib is recommen- especially if a targetable resistance mechanism is identi- fi fi ded as rst-line therapy for patients with RET fusion- ed [III, B].\nZygoura of Frontier Science Foundation Hellas provided JM reports fees paid to her institution as an invited review and validation of the ESMO-MCBS scores. Nicola speaker from AstraZeneca, Boehringer Ingelheim, BMS, MSD fi Latino (ESMO Scienti c Affairs staff) provided coordination and Roche; fees paid to her institution for expert testimony and support of the ESMO-MCBS scores and Angela Cor- from AstraZeneca, Boehringer Ingelheim and MSD; fees paid storphine of KMC provided medical writing and editing to her institution for travel expenses from Ipsen. support in the preparation of the ESMO-MCBS table; this TSM reports personal fees as an invited speaker from support was funded by ESMO. Dr Jordi Remón Masip (on AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, Amoy behalf of the ESMO Translational Research and Precision Diagnostics, BeiGene, Boehringer Ingelheim, BMS, Daiichi Medicine Working Group) and Dr Svetlana Jezdic (ESMO Sankyo, Daz Group, Eli Lilly, Fishawack Facilitate, InMed Medical Affairs Advisor) provided validation support for Medical Communication, Janssen, Jiahui Holdings Co., ESCAT scores. Matt Hellmann provided initial writing sup- LiangYiHui Healthcare, Lucene Health Inc., Lunit USA, Inc., port during the conception of this guideline. MD Health, Medscape/WebMD, Merck Serono, MIRXES, MSD, Novartis, OrigiMed, PeerVoice, PER, Permanyer SL, fi fi P zer, Prime Oncology, Research to Practice, Roche, Sano - FUNDING Aventis, Shanghai BeBirds Translation & Consulting Co., No external funding has been received for the preparation Taiho Pharmaceutical Co., Takeda and Touch Medical Me- of this guideline. Production costs have been covered by dia; personal fees for advisory board membership from ESMO from central funds. AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Berry Oncology, Blueprint Medicines, Boehringer Ingelheim, BMS, C4 Therapeutics, Cirina Ltd, DISCLOSURE Covidien LP, CStone Pharma, Curio Science, D3 Bio Ltd, Da LEH reports personal fees as an invited speaker from Ben- Volterra, Daiichi Sankyo, Eisai, Eli Lilly, Fishawack Facilitate, ecke, Medtalks and VJOncology; personal fees for partici- G1 Therapeutics, Gilead Sciences, Gritstone Oncology, pation in mentorship programme funded by AstraZeneca; Guardant Health, Hengrui, Ignyta, Incyte, Inivata, IQVIA, personal fees for travel support from Roche; personal fees Janssen, Lakeshore Biotech, Loxo Oncology, Lucene Health as member of the committee that revised the Dutch Inc., Lunit USA, Inc., Medscape/WebMD, Merck Serono, guidelines on NSCLC, brain metastases and leptomeningeal Mirati Therapeutics, MiRXES, MoreHealth, MSD, Novartis, fi metastases; fees paid to her institution for an educational OrigiMed, OSE Immunotherapeutics, P zer, Puma Tech, fi webinar from Janssen; fees paid to her institution for Qiming Development, Roche, Roche/Genentech, Sano - advisory board membership from Amgen, Bristol-Myers Aventis, SFJ Pharmaceutical Ltd, Synergy Research, Takeda, Squibb (BMS), Boehringer Ingelheim, Janssen, Lilly, Merck, Tigermed, Vertex Pharmaceuticals, Virtus Medical and fi Merck Sharp & Dohme (MSD), Novartis, P zer, Roche and Yuhan; personal fees as the Chairman for ACT Genomics- Takeda; fees paid to her institution as an invited speaker Sanomics Group; personal fees as a member of the board from AstraZeneca, Bayer, high5oncology, Lilly and MSD; fees of directors from AstraZeneca and HutchMed; holds stocks/ paid to her institution for interview sessions from Roche; shares from AstraZeneca, Aurora Tele-Oncology, Biolidics fees paid to her institution for podcast appearance from Ltd, HutchMed and Sanomics Ltd.; institutional funding Takeda; institutional research grants from AstraZeneca, from AstraZeneca, BMS, Clovis Oncology, G1 Therapeutics, fi fi Boehringer Ingelheim, Roche, Takeda, P zer and Merck; Merck Serono, MSD, Novartis, P zer, Roche, SFJ Pharma- institutional funding as a local principal investigator (PI) ceuticals,Takeda and XCovery; non-remunerated roles as an from AbbVie, AstraZeneca, Blueprint Medicines, Gilead, invited speaker with AstraZeneca, Aurora Tele-Oncology, GlaxoSmithKline (GSK), Merck Serono, Mirati, MSD, Novar- Lunit USA, Inc. and Sanomics Ltd and for an advisory role tis, Roche and Takeda; non-remunerated roles as chair for with geneDecode; non-remunerated leadership roles with metastatic NSCLC of the lung cancer group for European American Society of Clinical Oncology (ASCO), Asian Organisation for Research and Treatment of Cancer (EORTC) Thoracic Oncology Research Group (ATORG), Chinese Lung and as the secretary of the studies foundation for Neder- Cancer Research Foundation Limited (CLCRF), Chinese So- landse Vereniging van Artsen voor Longziekten en Tuber- ciety of Clinical Oncology (CSCO), Hong Kong Cancer Fund culose (NVALT). (HKCF), Hong Kong Cancer Therapy Society (HKCTS), IASLC ’ KK reports personal fees as an invited speaker from and St. Stephen s College & Prep School (Hong Kong). Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, UN reports fees paid to her institution as an invited fi Medscape, Merck Serono, MSD, Novartis, P zer, Prime speaker from MSD; fees paid to her institution for advisory Oncology, Roche and Roche Diagnostics/Ventana; personal board membership and a writing engagement from Astra- fees for consultancy and advisory board membership from Zeneca; institutional funding as a coordinating PI for Bayer; AbbVie, Amgen, AstraZeneca, Bayer, Debiopharm, Diac- non-remunerated roles as a PI for clinical trials funded by fi eutics, Janssen, Merck Serono, MSD, Novartis, P zer, Deutsche Krebshilfe and as a member of the board of di- ‘ ’ Regeneron, Roche and Roche Diagnostics/Ventana; non- rectors and vice-chair of Strahlenschutzkommission from remunerated roles as the past Pathology Committee Chair the German Commission on Radiological Protection. for International Association for the Study of Lung Cancer AP reports personal fees as an invited speaker from Astra- (IASLC) and member of the UK Lung Cancer Consortium. Zeneca,BoehringerIngelheim,EliLilly,Janssen,Mundipharma",
      "start_page": 1,
      "end_page": 15
    }
  ]
}